Mp15-01 Novel Urine-Based Biomarker to Distinguish Muscle-Invasive From Non-Muscle Invasive Bladder Cancer–a Multicentric Approach

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-01 NOVEL URINE-BASED BIOMARKER TO DISTINGUISH MUSCLE-INVASIVE FROM NON-MUSCLE INVASIVE BLADDER CANCER–A MULTICENTRIC APPROACH Barbara Koeditz, Lucas Kastner, Constantin Rieger, Sofia Semko, Maksyn Pikul, Enno Storz, Throsten Ecke, Friederike Linden, Ralph Wirtz, Richard Weiten, Melanie von Brandenstein, and Axel Heidenreich Barbara KoeditzBarbara Koeditz , Lucas KastnerLucas Kastner , Constantin RiegerConstantin Rieger , Sofia SemkoSofia Semko , Maksyn PikulMaksyn Pikul , Enno StorzEnno Storz , Throsten EckeThrosten Ecke , Friederike LindenFriederike Linden , Ralph WirtzRalph Wirtz , Richard WeitenRichard Weiten , Melanie von BrandensteinMelanie von Brandenstein , and Axel HeidenreichAxel Heidenreich View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The truncated variant of mitogen-activated protein kinase p38 (MAPK p38), Mxi-2 is associated with the occurrence and progression of renal cell carcinoma and prostate cancer (PCa). Furthermore, Vimentin3 (Vim3)represent the truncated variant of vimentin, a key structural protein. The expression of Vim3 has already been linked to the presence of PCa biomarkers in serum, which facilitates the detection of renal cell carcinoma. Ouraim was to ascertain the potential utility of Mxi-2 and Vim3 as potential biomarkers for stratification between non-muscle invasive (NMBIC) and muscle-invasive bladder cancer (MBIC). METHODS: Immunohistochemical and immunofluorescence analysis of Mxi-2 and Vim3 were determined in localized urothelial carcinoma (n=30). Furthermore, corresponding urine samples of patient with localized tumors (n=100) were analyzed by ELISA. Subsequently, we validated our findings by analyzing an independent validation cohort comprising n=365 urothelial carcinoma urines. RESULTS: We found a statistically significant higher expression of Mxi-2 and Vim3 in patients afflicted with MIBC (p<0.001) compared to NMIBC. For Mxi-2 a sensitivity of 92% and specificity of 88% and for Vim3 a sensitivity of 82% and specificity of 84% could be determined in our cohort from the University Hospital Cologne. Moreover, in the independent validation cohort Mxi-2 determination showed a sensitivity of 80% and a specificity of 94%, while Vim3 showed a specificity of 80% and a sensitivity of 75%. The evaluation of Mxi-2 and Vim3 in patient urine achieves better sensitivity and specificity compared to existing urine test system for bladder cancer such as NMP22, BTA stat and Uromonitor. CONCLUSIONS: The determination of Mxi-2 and Vim3 in urine enables rapid and cost-effective differentiation between NMIBC and MIBC with a high diagnostic accuracy for tailored surgical and therapeutic evaluation. Prospective validation of urine-based prediction of muscle invasiveness is ongoing in the prospective, multicenter Bladder BRIDGister study. In addition, biomarker results are being compared with multiparametric MRI to provide an integrated, non-invasive platform for robust MIBC classification prior to surgery. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e229 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Barbara Koeditz More articles by this author Lucas Kastner More articles by this author Constantin Rieger More articles by this author Sofia Semko More articles by this author Maksyn Pikul More articles by this author Enno Storz More articles by this author Throsten Ecke More articles by this author Friederike Linden More articles by this author Ralph Wirtz More articles by this author Richard Weiten More articles by this author Melanie von Brandenstein More articles by this author Axel Heidenreich More articles by this author Expand All Advertisement PDF downloadLoading ...